Copyright 2006 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2006
Objectives: The primary objective of this clinical trial for patients with stage III/IV resectable squamous cell carcinoma of the head and neck (SCCHN) was to demonstrate the feasibility and safety of a vaccine prepared by feeding apoptotic autologous tumor (AuTu) cells to dendritic cells (DCs) and delivered intranodally under ultrasound guidance. The secondary objective was to demonstrate immune responses to the vaccine using interferon gamma (IFN-γ) ELISPOT assays.
Whiteside TL, Ferris RL, Myers EN, Tublin M, Kiss J, Johnson R, Johnson JT. S012 Dendritic Cell (DC)-Based Vaccine for Patients With SCCHN Using Autologous Tumor Cells as Immunogens. Arch Otolaryngol Head Neck Surg. 2006;132(8):840. doi:10.1001/archotol.132.8.840-b